Global Oncology Academy

Understanding the Growing Burden of Early-Onset CRC
Understanding the Growing Burden of Early-Onset CRC
On the Frontlines of Colorectal Cancer
Understanding the Growing Burden of Early-Onset CRC
- Ryan Quigley
- Christopher Cann, MD
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
CME/CE
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
0.25 credits
- Benjamin Levy, MD
0.25 credits
Integrating Molecular Testing into NSCLC Care
Integrating Molecular Testing into NSCLC Care
Project Oncology®
Integrating Molecular Testing into NSCLC Care
- Geoffrey Oxnard, MD
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
AudioAbstracts
Improving BCC Screening in Childhood Cancer Survivors Through Risk Modeling
- Ryan Quigley
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Project Oncology®
Neoadjuvant Nivolumab With or Without Ipilimumab in Resectable CSCC
Smarter Screening for Non-Small Cell Lung Cancer
Smarter Screening for Non-Small Cell Lung Cancer
Project Oncology®
Smarter Screening for Non-Small Cell Lung Cancer
- Jobelle Baldonado, MD
Recognizing High-Risk Profiles for NSCLC
Recognizing High-Risk Profiles for NSCLC
Project Oncology®
Recognizing High-Risk Profiles for NSCLC
- Jobelle Baldonado, MD
Oncogenic Drivers in Never-Smokers with NSCLC
Oncogenic Drivers in Never-Smokers with NSCLC
Project Oncology®
Oncogenic Drivers in Never-Smokers with NSCLC
- Apar Kishor Ganti, MD, MS

Medical News

Medical News
Gut Microbiome and Checkpoint Immunotherapy: Reporting Recent Synthesis
03/11/2026
Read more
Medical News
ProstACT Part 1: TLX591-Tx Safety, Dosimetry, and Implications for Part 2
03/11/2026
Read more
Medical News
Label‑Free Multiphoton Microscopy + ML for HCC: Accuracy and Tumor Border Maps
03/11/2026
Read more
Medical News
Human hIEC Model Reports High Accuracy for Detecting Drug-Induced Intestinal Barrier Damage
03/10/2026
Read more

See more news

CME/CE

The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
MinuteCE®
The Safety Equation: Managing Adverse Events Associated With CSF1R Inhibitors in TGCT
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
MinuteCE®
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
1.00 program credit
- A.J. Gelderblom, MD, PhD
1.00 program credit
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
MinuteCE®
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
1.00 program credit
- A.J. Gelderblom, MD, PhD
- Chelsea Cole, MD
1.00 program credit
All Sides of the Joint: Integrated TGCT Care Across Specialties
All Sides of the Joint: Integrated TGCT Care Across Specialties
MinuteCE®
All Sides of the Joint: Integrated TGCT Care Across Specialties
1.00 program credit
- A.J. Gelderblom, MD, PhD
- Michiel van de Sande, MD, PhD
- Chelsea Cole, MD
1.00 program credit

Clinical Practice

Decoding Co-Mutations in HR+, HER2- Metastatic Breast Cancer
Decoding Co-Mutations in HR+, HER2- Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Decoding Co-Mutations in HR+, HER2- Metastatic Breast Cancer
- Abirami Sivapiragasam
Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
On the Frontlines of AML/ALL
Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
- Charles Turck, PharmD, BCPS, BCCCP
- Lena Winestone, MD, MSHP
Cosibelimab Delivers Durable Responses in Advanced CSCC
Cosibelimab Delivers Durable Responses in Advanced CSCC
Project Oncology®
Cosibelimab Delivers Durable Responses in Advanced CSCC
Expanding Molecular Testing in Community NSCLC Care
Expanding Molecular Testing in Community NSCLC Care
Project Oncology®
Expanding Molecular Testing in Community NSCLC Care
- Apar Kishor Ganti, MD, MS

Programs

A New Era of Hope in Non-Small Cell Lung Cancer Care
A New Era of Hope in Non-Small Cell Lung Cancer Care
Project Oncology®
A New Era of Hope in Non-Small Cell Lung Cancer Care
- Geoffrey Oxnard, MD
Addressing Unmet Needs in First-Line mTNBC Care
Addressing Unmet Needs in First-Line mTNBC Care
On the Frontlines of Metastatic Breast Cancer
Addressing Unmet Needs in First-Line mTNBC Care
- Jennifer Caudle, DO, FACOFP
- Alexis Ann LeVee, MD
Optimizing Care for Older Adults With FLT3-Mutated AML
Optimizing Care for Older Adults With FLT3-Mutated AML
Global Oncology Academy
Optimizing Care for Older Adults With FLT3-Mutated AML
- Ryan Quigley
- Nicholas Short, MD
Biomarker-Guided Treatment in ER+, HER2- Metastatic Breast Cancer
Biomarker-Guided Treatment in ER+, HER2- Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Biomarker-Guided Treatment in ER+, HER2- Metastatic Breast Cancer
- Maxwell Llyod, MD
- Ryan Quigley